Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
A more comprehensive dataset on JANX007 sends the group’s stock down.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
The agency approved eight oncology products over the month.
Varegacestat’s pivotal study reads out imminently.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
The pivotal Harmoni-GI3 study has started enrolling patients.
